Genomic Therapy Matching in Rare and Refractory Cancers
Frank P. Lin, Subotheni Thavaneswaran, John P. Grady, Christine E. Napier et autres
au (code pays fourni par la source)
8 citations
JAMA Oncology
Amy Prawira
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
55Publications signalées
1375Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Cancer Immunotherapy and BiomarkersHead and Neck Cancer StudiesColorectal Cancer Treatments and StudiesPARP inhibition in cancer therapyPancreatic and Hepatic Oncology Research
Les publications récentes
Abstract CT047: Interim results from the phase 1/2 ABILITY-1 study of a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine in patients with advanced solid tumors
Victoria Atkinson, Warren Brenner, Jacqueline T. Brown, Luis Cabezón‐Gutiérrez et autres
au, us, es, kr, it (code pays fourni par la source)
2 citations
Cancer Research
Abstract CT259: Results from monotherapy dose escalation of MDNA11, a long-acting IL-2 superkine, in a phase 1/2 trial show evidence of single-agent activity in advanced solid tumors
Victoria Atkinson, Jesús Fuentes‐Antrás, Philippe L. Bédard, Warren Brenner et autres
au, ca, us, it (code pays fourni par la source)
6 citations
Cancer Research
Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study
Sarwan Bishnoi, Dusan Kotasek, Morteza Aghmesheh, Thomas Yau et autres
au, cn, hk, nl (code pays fourni par la source)
3 citations
Cancer
760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors
Minh D. To, Rosemina Merchant, Victoria Atkinson, Philippe L. Bédard et autres
au, ca, us, gb (code pays fourni par la source)
1 citation
Regular and Young Investigator Award Abstracts
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS ‐001 clinical trial
Alberto Hernando‐Calvo, Eoghan Ruadh Malone, Daphne Day, Amy Prawira et autres
ca (code pays fourni par la source)
6 citations
Cancer Medicine
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
Daphne Day, John Park, Jermaine Coward, Ben Markman et autres
au, nz (code pays fourni par la source)
7 citations
British Journal of Cancer
Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
Herbert H. Loong, Toshio Shimizu, Amy Prawira, Aaron C. Tan et autres
hk, jp, au, sg, nz, th, my, kr (code pays fourni par la source)
42 citations
ESMO Open
Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial.
Alberto Hernando‐Calvo, Eoghan Ruadh Malone, Daphne Day, Amy Prawira et autres
ca (code pays fourni par la source)
1 citation
Research Square
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Charu Aggarwal, Amy Prawira, Scott Antonia, Osama E. Rahma et autres
us, au (code pays fourni par la source)
150 citations
Journal for ImmunoTherapy of Cancer
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín, María Ochoa-de-Olza et autres
be, sg, es, us, jp, ca, it, au, de (code pays fourni par la source)
160 citations
Journal for ImmunoTherapy of Cancer
Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial
Alberto Hernando‐Calvo, Eoghan Ruadh Malone, Daphne Dai, Amy Prawira et autres
ca (code pays fourni par la source)
2 citations
Molecular Cancer Therapeutics
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.